Objective To summarise and compare the efficacy and safety of various oral anticoagulants
(dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents …

Objective To critically review the effectiveness of the novel oral anticoagulants (rivaroxaban,
dabigatran, ximelagatran, and apixaban) in the treatment of acute venous …

Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …

Background Historically, warfarin or aspirin have been the recommended therapeutic
options for the extended treatment (> 3 months) of VTE. Data from Phase III randomised …

Objective To determine the safety of direct oral anticoagulant (DOAC) use compared with
warfarin use for the treatment of venous thromboembolism. Design Retrospective matched …

Objective To evaluate efficacy and safety of oral anticoagulant regimens and aspirin for
extended venous thromboembolism (VTE) treatment. Methods We searched MEDLINE …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

The prevention and treatment of venous thromboembolism (VTE) remains a clinical
challenge, primarily owing to drawbacks associated with the use of heparins and vitamin K …

Objectives The aim was to perform a review of the efficacy and safety of new oral
anticoagulants (NOAs) in the management of venous thromboembolism (VTE). Methods …

Background Patients who have had an unprovoked deep venous thrombosis (DVT) or
pulmonary embolus (PE) are at a high risk for recurrent venous thromboembolism (VTE) …